Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Needham & Company Reiterate Buy on Seattle Genetics (SGEN) Following Adcetris Approval
August 18, 2015 11:12 AM EDTNeedham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) following the announced approval of Adcetris in Hodgkin's Lymphoma patients with high risk for relapse after stem cell transplant. Approval in this indication was based on the AETHERA... More
Leerink Partners Remain Bullish on Seattle Genetics (SGEN) Following FDA's Approval of Adcetris
August 18, 2015 10:13 AM EDTLeerink Partners reiterated an Outperform rating and $56.00 price target on Seattle Genetics (NASDAQ: SGEN) following the announced FDA approval of Adcetris. SGEN announced the approval after market close. The Adcetris will be used in the AETHERA setting for Hodgkins lymphoma patients at high... More
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS as Classical HL Treatment in Certain Patients
August 17, 2015 4:10 PM EDTSeattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. The approval is based on a phase 3 clinical trial called AETHERA that was designed to compare up to 16 cycles (approximately one year) of ADCETRIS therapy administered every three weeks following auto-HSCT to placebo. The primary endpoint was met with a significant improvement in median progression-free survival (PFS) of 42.9 months (95% CI: 30.4, 42.9) for... More
